Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

AEVIS VICTORIA SA

Investor Presentation • Oct 6, 2009

808_ip_2009-10-06_e005e837-bbf7-4958-a133-7eeaa926084e.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

GENOLIER SWISS MEDICAL NETWORK SA (GSMN.SW)PRESENTATION OF THE 1H2009 RESULTS

2009 –FOCUS ON HEALTHCARE

GROUP STRUCTURE

CORPORATEGOVERNANCE

Board of Directors

  • o Raymond Loretan – Executive Chairman
  • o Robert Pennone – Vice-chairman and Non chairman Non-Executive member
  • oAntoine Hubert – Managing Director
  • o Me Antoine Kohler – Non-Executive Executive member
  • o Dr Michael Schroeder – Non-Executive Executivemember
  • o Pr Hans-Reinhard Zerkowski –Non-Executive member

Important shareholders

ORGANISATIONAL CHART

VISION

  • Creation of a strong player in the private healthcare sector in Switzerland
  • Privilege quality and excellence
  • High operational flexibility
  • Become an undisputed leader in medical tourism in Switzerland
  • Offer a reliable private alternative to the public healthcaresystem

GROWTH STRATEGY

  • Create a network of private clinics present in various cantons and become a key player in Switzerland
  • Organic growth
  • o Continuous investments in state technologiesstate-of-the-art medical equipment and
  • Acquisitions and co-operations operations
  • Development of several regional platforms
  • oRespect each entity's local identity and corporate culture
  • oBetter local integration
  • oIntroductions to the local sanitary network
  • oBasis for further regional development
  • oBoard of Directors with local members

STRATEGIC DRIVERS

Customer value
Hospitality/High-
tech equipment/top
Physicians		 Branding
Local identity
Centre of excellence
Profitability Growth
Customer mix
Cost cuttings, MIS
Margin improvements
Asset lean/financing
Entrepreneurial spirit		 Acquisitions and
organic growth (rev-
enue per customer,
utilization, no of beds),
level of surgery, VIP's,
outpatient feeders

5 STATE-OF-THE-ART CLINICSIN THE ROMANDIE

1H2009 KEY FIGURES

  • 390 available beds
  • 371 admitting physicians
  • 591 employees (FTE)
  • 72 environmental services and outside lab employees
  • 6,540 surgical interventions

CLINIQUE DE GENOLIER

  • 150 admitting physicians
  • 250 employees (FTE)
  • 168 beds
  • 2,004 admissions (IPD) over 6 monthso10,997 OPD (Polyclinic)
  • 1,406 surgeries over 6 months
  • Key specialties
  • oOncology
  • oGeneral and digestive surgery
  • oOrthopaedics
  • oGynaecology and Senology (IORT)
  • oPlastic Surgery
  • Revenue breakdown
  • oInpatients (IPD) 69%
  • oOutpatients (OPD) 31%

CLINIQUE DE MONTCHOISI

  • 97 admitting physicians
  • 66 employees (FTE)
  • 21 beds
  • 5,360 admissions (IPD+OPD) over 6 months
  • 2,294 surgeries over 6 months
  • o1,532 ophtalmology
  • Key specialties
  • oOphtalmology
  • oOrthopaedics
  • oGynaecology
  • oPlastic surgery
  • Revenue breakdown
  • Inpatients (IPD) 51%
  • oOutpatients (OPD) 49%

o

CLINIQUE GÉNÉRALE

  • 98 admitting physicians
  • 109 employees (FTE)
  • 60 beds
  • 2,896 admissions over 6 monthsoOf which 723 ambulatory
  • 2,840 surgeries over 6 months
  • Key specialties
  • oOrthopaedics
  • oGynaecology
  • oGeneral surgery
  • oENT
  • oNeurosurgery
  • Revenue breakdown
    • oInpatients (IPD) 85%
    • oOutpatients (OPD) 15%

CLINIQUE VALMONT-GENOLIER

  • 6 admitting physicians
  • 109 employees (FTE)
  • 78 beds
  • 589 admissions over 6 months
  • Key specialties
  • oOrthopaedics
  • oNervous system
  • o Ambulatory consultations
    • •Neuropsychology, ergotherapy, physiotherapy,...
  • Revenue breakdown
  • oInpatients (IPD) 90%
  • oOutpatients (OPD) 10%

CENTRE MEDICO-CHIRURGICALCENTRE DE RADIO-ONCOLOGIE DE CHIRURGICAL DES EAUX-VIVESONCOLOGIE GENÈVE

  • 20 admitting physicians
  • 25 employees (FTE)
  • 19,313 consultations over 6 months
  • o15,385 CMEV (85/day)
  • o3,982 Centre de radio-oncologie (22/day)
  • Key specialties
  • oRadiotherapy
  • oOncology
  • oGynaecology
  • oPneumology
  • Paediatricso
  • Revenue breakdown
  • oOutpatients (OPD) 100%

LES HAUTS DE GENOLIER

  • Secured hotel residence providing medical care, located right next to Clinique de Genolier
  • 63 prestigious apartments with all modern technologies
  • Multidisciplinary team of 10 persons
  • Personalised medical treatments
  • Short and/or long stays, weekend packages

CUSTOMER MIX

HIGHLIGHTS OF 1H2009 PERFORMANCE

  • Group achieved a 11.2% growth in half year revenue to CHF 71.26 million
  • EBITDA increased by 67.1% from CHF 3.60 to CHF 6.02 million
  • Profit from operating activities (EBIT) is clearly beneficiary at CHF 2.06 million
  • Profit after tax result is CHF 4.73 million CHF 0.78 million for same period last yearversus a loss of
  • Well balanced revenue growth win-line with strategyth within each healthcare facility and
  • Challenging environment
  • oInternational economic crisis
  • oUncertain legal environment

CONSOLIDATED P&L

(
'0
)
1
0
0
C
H
F
x		 1
H
2
0
0
9		 1
H
2
0
0
8		 /
F
Y
2
0
0
8		 /
F
Y
2
0
0
7
C
l
i
d
d
t
o
o
e
e
e
e
n
s
a
r
v
n
u
s		 2
6
0
7
1,		 6
3
3
8
1
,		 2
8
1
7
4
4
,		 6
3
1
1
7
5
,
O
i
t
t
p
e
r
a
n
g
c
o
s
s		 (
2
3
)
6
5
4
,		 (
9
8
0
)
5
7
,		 (
3
8
0
)
1
1
7
,		 (
2
2
3
)
1
1
4
,
E
B
I
T
D
A		 6
0
1
7
,		 3
6
0
1
,		 1
0
4
6
4
,		 4
3
1
2
,
D
i
i
&
A
i
i
t
t
t
e
p
e
c
a
o
n
m
o
a
o
n
r
r
z		 (
)
3
9
5
9
,		 (
)
3
2
6
4
,		 (
)
7
3
8
0
,		 (
)
6
1
8
3
,
E
B
I
T		 2
0
8
5
,		 3
3
7		 3
0
8
4
,		 (
8
)
1,
7
1
l
T
i
t
t
t
o
a
n
e
r
e
s		 (
3
6
)
7		 (
2
0
)
5		 (
6
3
)
1,
1		 (
)
7
1
1
f
/
b
f
P
i
L
i
t
t
r
o
o
s
s
e
o
r
e
n
c
o
m
e
a
x		 1,
3
2
2		 (
8
)
1
3		 1,
9
3
6		 (
)
2
6
5
1
,
I
t
n
c
o
m
e
a
x		 3
9
7		 (
)
9
9		 (
)
6
3
3		 (
)
2
4
6
f
f
i
/
i
i
i
P
t
L
t
t
r
o
o
s
s
r
o
m
c
o
n
n
u
n
g
o
p
e
r
a
o
n
s		 9
1,
1
7		 (
2
8
2
)		 3
0
3
1,		 (
2
8
9
)
7
,
f
f
i
/
d
i
i
i
i
P
t
L
t
t
r
o
o
s
s
r
o
m
s
c
o
n
n
u
n
g
o
p
e
r
a
o
n
s		 3
0
0
8
,		 (
9
)
4
7		 (
3
9
)
1,
1		 (
3
3
)
5
f
i
/
N
P
L
t
t
e
r
o
o
s
s		 2
4
7
7
,		 (
9
)
7
7		 1
6
4		 (
3
2
3
2
)
,

REVENUE –EBITDA

EBITDA AND EBITDA MARGIN

CONSOLIDATED OPERATING CASH FLOW*

CASH FLOW

(
'0
)
1
0
0
C
H
F
x		 1
H
2
0
0
9		 1
H
2
0
0
8
f
f
h
l
i
i
i
i
N
t
t
t
t
e
o
o
o
e
e
c
a
s
w
r
m
p
r
a
n
g
a
c
v
s		 6
0
6
2
,		 9
4
4
4
,
h
f
l
d
i
i
i
i
i
i
N
t
t
t
t
e
c
a
s
o
w
u
s
e
n
n
v
e
s
n
g
a
c
v
e
s		 (
3
3
)
4
5
,		 (
2
0
2
8
)
,
h
f
l
d
i
f
i
i
i
i
i
N
t
t
t
e
c
a
s
o
s
e
n
n
a
n
c
n
g
a
c
e
s
w
u
v		 (
)
1,
8
9
5		 (
)
1,
6
0
5
(
i
)
/
d
i
h
d
h
i
l
N
t
t
e
n
c
e
a
s
e
e
c
e
a
s
e
n
c
a
s
a
n
c
a
s
e
q
a
e
n
s
r
r
u
v		 (
)
1
8
6		 1,
3
1
1
f
C
h
d
h
i
l
d
h
i
d
t
t
t
a
a
a
e
a
e
a
e
o
e
e
o
s
n
c
s
q
u
v
n
s
n
p
r		 9
4
4
5
,		 0
3
7
1
,

CONSOLIDATEDBALANCE SHEET

(
1,
0
0
0
C
)
H
F
x		 1
/
2
0
0
9
H		 1
/
2
0
0
8
H		 /
2
0
0
8
F
Y		 /
2
0
0
F
Y
7
A
t
s
s
e
s
N
t
t
o
n
c
u
r
r
e
n
a
s
s
e
s		 2
9
9
8
1
4
,		 2
8
0
1
1
7
,		 2
8
6
8
1
1
,		 2
6
9
9
6
1
,
C
t
t
u
r
r
e
n
a
s
s
e
s		 6
8
4
1
5
,		 3
8
0
4
1
,		 3
2
4
7
7
,		 3
0
8
4
7
,
l
T
t
A
t
o
a
s
s
e
s		 8
9
6
1
1
5
,		 9
1
7
1,
7
1		 1
7
1,
4
4
5		 0
0
1
7
7
4
,
i
E
t
q
u
y
h
l
S
i
t
a
r
e
c
a
p
a		 '0
'0
3
3
1
1
0
0
3		 2
8
2
0
3
,		 2
8
2
0
3
,		 2
8
2
0
3
,
h
S
i
a
r
e
p
r
e
m
u
m		 9
6
6
4
5
,		 9
1,
4
2
7		 9
1,
3
5
3		 9
1,
3
5
3
h
T
r
e
a
s
u
r
y
s
a
r
e
s		 (
)
2
9
6
6
,		 (
)
2
8
7
9
,		 (
)
2
8
6
8
,		 (
)
2
8
5
4
,
l
d
d
f
d
h
A
i
i
t
t
t
c
c
u
m
u
a
e
e
c
a
n
o
e
r
r
e
s
e
r
v
e
s		 1,
8
5
9		 (
)
4
0
8
2
,		 (
)
2
9
8
9
,		 (
)
3
2
2
7
,
l
i
T
t
t
o
a
e
q
u
y		 1
2
6
8
6
4
,		 1
1
2
9
9
2
,		 1
1
4
0
2
2
,		 1
1
3
7
9
8
,
i
b
i
l
i
i
L
t
a
e
s
l
b
l
N
i
i
i
i
t
t
o
n
-c
e
n
a
e
s
u
r
r		 1
1,
6
2
3		 7
4
0
2
,		 8
7
6
8
,		 6
2
2
3
,
l
b
l
C
i
i
i
i
t
t
e
n
a
e
s
u
r
r		 5
0
6
6
9
,		 5
1,
5
7
7		 4
8
6
5
5
,		 5
0
6
8
3
,
l
l
i
b
i
l
i
i
T
t
t
o
a
a
e
s		 6
2
2
9
2
,		 5
8
9
7
9
,		 5
7
4
2
3
,		 5
6
9
0
6
,
l
i
d
l
i
b
i
l
i
i
T
t
t
t
o
a
e
q
a
n
a
e
s
u
y		 1
8
9
1
5
6
,		 1
7
1,
9
7
1		 '4
1
7
1
4
5		 1
7
0
7
0
4
,

SEGMENT REPORTING

(
'0
)
1
0
0
C
H
F
x		 1
H
2
0
0
9		 1
H
2
0
0
8
R
e
e
n
e
v
u		 E
B
I
T
D
A		 S
t
t
e
g
m
e
n
a
s
s
e
s		 R
e
e
n
e
v
u		 E
B
I
T
D
A		 S
t
t
e
g
m
e
n
a
s
s
e
s
G
l
i
e
n
o
e
r		 3
8
6
8
7
,		 8
3
2
5
,		 9
4
1,
1
5		 3
3
4
1
7
,		 0
6
5
1
,		 0
3
8
8
4
,
h
i
i
M
t
o
n
c
o
s		 8
7
1
4
,		 1,
3
5
4		 9
7
5
7
,		 8
4
0
0
,		 1,
2
5
3		 1
0
2
1
5
,
l
G
l
i
V
t-
a
m
o
n
e
n
o
e
r		 0
3
7
5
,		 2
6
5		 9
2
4
4
,		 0
7
7
7
,		 2
0
5		 9
3
3
9
,
é
é
l
i
i
l
C
G
n
q
u
e
n
r
a
e		 1
4
4
8
6
,		 2
2
0
7
,		 1
6
7
2
9
,		 1
3
0
2
3
,		 1,
7
1
9		 1
6
6
2
1
,
C
M
E
V		 2
9
0
8
,		 6
0
1		 0
8
9
1
7
,		 - - -
l
T
t
o
a		 7
1,
0
2
9		 1
0
2
5
9
,		 8
8
7
0
4
,		 6
3
3
6
6
,		 8
8
5
9
,		 7
6
5
6
3
,

DISTRIBUTION OF REVENUE

2009 PROJECTS – KLINIK BETHANIEN

Exclusive negotiations

Acquisition of at least 90% of Privat Klinik Bethanien

Why Bethanien?

  • o Well-know private clinic in Zurichknow
  • oStrong brand
  • oMatching company cultures
  • oIndependent doctors
  • oHigh quality care and hospitality
  • Good basis for cooperation and synergies

KLINIK BETHANIEN

  • 180 admitting physicians
  • 230 employees (FTE)
  • 111 available beds
  • 5,000 patients per year
  • 3,929 surgeries and 451 deliveries
  • Key specialties
  • oGeneral surgery
  • oGynaecology and obstetrics
  • oMaxillofacial surgery
  • oENT
  • oOrthopaedics
  • oPlastic and reconstructive surgery
  • oUrology and visceral surgery

2009 OBJECTIVES

  • Organic growth / patient mix improvement
  • Development of the network and synergies
  • Margin improvement (CGF, CDV, CDM)
  • Development of productivity (CDG)
  • Continuous efforts to reduce overhead costs
  • Development of innovative medical treatments

More from AEVIS VICTORIA SA

Earnings Release 2025
Dec 29
Earnings Release 2025
Dec 29
Earnings Release 2025
Dec 29
Earnings Release 2025
Dec 29
Earnings Release 2025
Nov 3
Earnings Release 2025
Nov 3
Earnings Release 2025
Nov 3
Earnings Release 2025
Nov 3
Earnings Release 2025
Sep 18
Earnings Release 2025
Sep 18
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.